Altimmune (ALT) announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Jordt succeeds Jose Ochoa, who is leaving Altimmune to pursue other opportunities. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company (LLY)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALT:
- Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
- Altimmune Appoints Raymond Jordt as Chief Business Officer
- Altimmune 24-week NAFLD data ‘strong and encouraging,’ says Piper Sandler
- Altimmune announces topline results from 24-week trial of pemvidutide
- Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)